Background
==========

Uterine cervical cancer is the fourth most common malignancy in women, with an estimated 528,000 new cases reported worldwide in 2012 \[[@b1-medscimonit-24-6387],[@b2-medscimonit-24-6387]\]. On initial diagnosis, 13% of women with uterine cervical cancer are at an advanced stage, which results in reduced patient survival \[[@b3-medscimonit-24-6387],[@b4-medscimonit-24-6387]\].

In women with cervical cancer, metastasis to bone is one of the most common sites, which may lead to skeletal-related events, including bone pain and pathological fracture, and to a reduced patient quality of life \[[@b5-medscimonit-24-6387],[@b6-medscimonit-24-6387]\]. The incidence of bone metastases in women with uterine cervical cancer has been reported to range from 1.1--29.0% \[[@b6-medscimonit-24-6387]--[@b10-medscimonit-24-6387]\]. Early diagnosis and proper treatment of bone metastases in cervical cancer can prevent or reduce symptoms such as bone pain \[[@b11-medscimonit-24-6387]\]. Currently, there are no screening guidelines for the detection of bone metastases in women who present with cervical cancer. The identification of risk factors for the development of bone metastases could ensure that patients with a high risk for developing bone metastases are thoroughly investigated, and, if possible, treated at an early stage or provided with appropriate preventive treatment. A previously published study showed that clinical and pathological factors, including the presence of cervical adenocarcinoma, advanced stage (IIB--IV), were significantly associated with earlier occurrence of bone metastases in cervical cancer, but this study had a small sample size \[[@b11-medscimonit-24-6387]\]. Therefore, studies with larger study populations are needed.

Although the development of novel systemic therapies has contributed to significant improvements in prognosis for uterine cervical cancer, the presence of bone metastases results in reduced patient survival \[[@b6-medscimonit-24-6387],[@b11-medscimonit-24-6387]\]. A series of studies reported the median survival time of 7--12 months among women with cervical cancer who had bone metastases, and more than 60% of patients with cervical cancer died within six months after being diagnosed with bone metastases \[[@b6-medscimonit-24-6387],[@b11-medscimonit-24-6387]--[@b14-medscimonit-24-6387]\]. Therefore, there is a need to study the prognostic factors for bone metastases and provide proper treatment to the high-risk patients with cervical cancer \[[@b15-medscimonit-24-6387]\]. A previously published study that included 68 patients with cancer of the uterine cervix also showed that when compared with elderly patients, young patients with bone metastases who were aged less than 45 years, had a poorer prognosis \[[@b16-medscimonit-24-6387]\]. It has also been reported that patients with cancer of the uterine cervix who have a higher tumor TNM stage and several sites for bone metastases had a worse survival rate \[[@b11-medscimonit-24-6387]\]. However, not only are large study sample sizes required, but real-world evidence is still required to determine the prognostic factors for bone metastases in patients with cancer of the uterine cervix.

The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI) was established in 1973, which includes approximately 30% of the total US population and provides an important data source for epidemiologic analysis \[[@b17-medscimonit-24-6387]\]. Therefore, the aims of this study were to analyze the SEER database to determine the incidence and the risk factors for bone metastases in women with bone metastases on initial diagnosis of uterine cervical cancer, and to determine the overall survival, prognosis, and risk factors for patients who present with cervical cancer associated with bone metastases.

Material and Methods
====================

Study population
----------------

Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The SEER \*Stat 8.3.5 software (*<https://seer.cancer.gov/data/>*) was used to access the database. Since the details of metastases were not recorded before 2010, patients with primary cancer of the uterine cervix who were aged ≥18 years at diagnosis, between 2010--2015, were analyzed. The site code ICD-O-3 (International Classification of Diseases for Oncology-3)/WHO 2008 was restricted to 'cervix uteri.' The exclusion criteria for patient selection included patients diagnosed with carcinoma *in-situ*, benign or borderline tumors, patients diagnosed at autopsy or via death certificates, patients who had not been investigated for bone metastases, or who did not undergo follow-up.

Patients who were identified as having histologically-confirmed cervical cancer from 1^st^ January 2010 to 31^st^ December 2015 were included in the analysis of the incidence and risk factors for bone metastases. Women who were diagnosed with cancer of the uterine cervix with bone metastases between 2010--2014 (with at least one year of follow-up) were included to conduct survival analysis and to investigate the prognostic factors for bone metastases.

Ethics statement
----------------

The SEER database is an open public database, and the release of data from the SEER database does not require informed patient consent because cancer is a reportable disease in every state of the United States. The present study complied with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards and the study was approved by the Research Ethics Board of the Tianjin First Central Hospital (2018N012KY).

Statistical analysis
--------------------

The following patient demographic and clinical characteristics were included: age (≤40, 41--64 years, and ≥65 years); ethnicity (Caucasian, black, others); marital status (married and unmarried); insurance status (insured and uninsured); primary tumor stage (T-stage: T1, T2, T3 and T4); regional lymph node stage (N-stage: N0 and N1); histology, including squamous, adenocarcinoma, adenosquamous, and other types, including large cell neuroendocrine carcinoma (35 patients), small cell carcinoma, NOS (175 patients), neuroendocrine carcinoma, NOS (86 patients), malignant mesonephroma (23 patients), leiomyosarcoma, NOS (28 patients); tumor grade, G1 or well-differentiated, G2 or moderately-differentiated, and G3, or poorly-differentiated, undifferentiated or anaplastic; and the presence of lung metastases, liver metastases, and brain metastases.

The differences in the incidence of bone metastases between the categorical variables were analyzed by the chi-squared (χ^2^) test or rank sum test. The risk factors for women with cancer of the uterine cervix with bone metastases at initial diagnosis were determined primarily by univariate logistic regression analysis. Characteristics with P\<0.05 in the univariate logistic regression analysis were then further analyzed using a multivariate logistic regression model. The primary outcome of the survival analysis was the overall survival, which was defined from the time of diagnosis of uterine cervical cancer to all causes of death. Kaplan-Meier curves were used to test the overall survival rate, and the log-rank test evaluated the survival differences. Also, multivariate Cox proportional hazard regression analysis was performed for analyzing the prognostic factors for bone metastases. Univariate Cox regression analysis was performed for the surgical treatments of the primary site (yes or no). All statistical analysis was performed using SPSS version 23.0 (IBM Corporation, Armonk, NY, USA). MedCalc version 15.2.2 statistical software was used to analyze survival data. A P-value \<0.05 was considered as statistically significant.

Results
=======

Demographic and clinical characteristics
----------------------------------------

A total of 19,363 women with cancer of the uterine cervix met the criteria for inclusion in the study ([Figure 1](#f1-medscimonit-24-6387){ref-type="fig"}). The mean patient age was 50.86±14.97 years, most patients were Caucasian (74.6%), and 53.0% were unmarried. Among these patients, 364 patients with cervical cancer and bone metastases underwent clinical follow-up for at least one year (mean survival, 9.94±12.38 months), and the mean age was 56.43±13.78 years. The demographic and clinical characteristics of the patients included in the study are shown in [Table 1](#t1-medscimonit-24-6387){ref-type="table"}.

Incidence of bone metastases
----------------------------

In total, 469 women with cancer of the uterine cervix were diagnosed with bone metastases on initial diagnosis (2.42%). Patients ≥65 years of age (3.47%) presented with a significantly increased incidence of bone metastases when compared with patients in the lower age groups (χ^2^=63.55, *P*\<0.001). Moreover, patients with unmarried status (χ^2^=6.62, *P*=0.01), higher T stage (χ^2^=469.49, *P*\<0.001), N stage (χ^2^=428.72, *P*\<0.001), non-squamous or non-adenocarcinoma (χ^2^=116.15, *P*\<0.001), poor differentiated grade (χ^2^=107.18, *P*\<0.001) and with lung (χ^2^=1548.09, *P*\<0.001), liver (χ^2^=1497.94, *P*\<0.001) and brain metastases (χ^2^=446.54, *P*\<0.001) showed higher BM incidence than the others. However, the incidence of bone metastases showed no significant differences between different ethnic groups (χ^2^=4.10, *P*=0.13) and between insurance status (χ^2^=1.93, *P*=0.17) ([Table 1](#t1-medscimonit-24-6387){ref-type="table"}).

Risk factors for developing bone metastases
-------------------------------------------

Univariate logistic analysis showed that the following factors were all significantly associated with the development of bone metastases: older patient age (OR=3.34; 95% CI, 2.44--4.58; P\<0.001), unmarried status (OR=1.29; 95% CI, 1.06--1.56; P=0.01), higher T-stage (OR=14.69; 95% CI, 10.20--21.15; P\<0.001), higher N-stage (OR=7.20; 95% CI, 5.80--8.94; P\<0.001), non-squamous and non-adenocarcinoma histological type (OR=2.93; 95% CI, 2.33--3.67; P\<0.001), poorly-differentiated grade (G3) (OR=8.68; 95% CI, 4.45--16.95; P\<0.001), the presence of lung metastases (OR=20.16; 95% CI, 16.44--24.72; P\<0.001), liver metastases (OR=25.36; 95% CI, 20.04--32.09; P\<0.001), and brain metastases (OR=27.83; 95% CI, 17.46--44.36; P=0.01).

Multivariate logistic regression analysis showed that a higher T-stage, a higher N-stage, non-squamous and non-adenocarcinoma histological type, higher grade, and the presence of lung, liver, and brain metastases were all significantly associated with the early development of bone metastases ([Table 2](#t2-medscimonit-24-6387){ref-type="table"}, [Figure 2](#f2-medscimonit-24-6387){ref-type="fig"}).

Survival analysis and prognostic factors for bone metastases
------------------------------------------------------------

When women with cancer of the uterine cervix were diagnosed with bone metastases, their survival was significantly reduced. The overall one-year and three-year survival rate of the cohort was 85% and 69%, respectively, which decreased to 32% and 11%, respectively following a diagnosis of bone metastases. Of the 364 patients with cervical cancer who had bone metastases on initial diagnosis (diagnosed between 2010--2014), the median overall survival time was 6.00 months (95% CI, 5.05--6.95 months) ([Figure 3A](#f3-medscimonit-24-6387){ref-type="fig"}). Kaplan-Meier analysis showed the overall survival was significantly reduced in women of older age (P=0.01) ([Figure 3B](#f3-medscimonit-24-6387){ref-type="fig"}), unmarried status (P=0.004) ([Figure 3C](#f3-medscimonit-24-6387){ref-type="fig"}), non-squamous and non-adenocarcinoma histological type (P=0.046) ([Figure 3D](#f3-medscimonit-24-6387){ref-type="fig"}) and with lung metastases (P\<0.001) ([Figure 3E](#f3-medscimonit-24-6387){ref-type="fig"}), liver metastases (P\<0.001) ([Figure 3F](#f3-medscimonit-24-6387){ref-type="fig"}) and brain metastases (P\<0.001) ([Figure 3G](#f3-medscimonit-24-6387){ref-type="fig"}). Patients with surgical treatment of the primary site did not have a significantly increased overall survival compared with those without surgery (P\>0.05).

Multivariate Cox regression analysis showed that unmarried status (HR=1.34; 95% CI, 1.04--1.72; P=0.02) was associated with poor overall survival, with a median survival time of only five months, while the median survival time of married patients was ten months. Also, the presence of lung metastases (HR=1.48; 95% CI, 1.15--1.89; P=0.002), liver metastases (HR=1.42; 95% CI, 1.07--1.87; P=0.02), and brain metastases (HR=2.64; 95% CI, 1.57--4.43; P\<0.001) were all associated with poor prognosis ([Table 3](#t3-medscimonit-24-6387){ref-type="table"}, [Figure 2](#f2-medscimonit-24-6387){ref-type="fig"}).

Discussion
==========

To our knowledge, the present study involved the analysis of the largest population of women with cancer of the uterine cervix with bone metastases conducted at this time. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database was analyzed for the incidence and survival rates of women diagnosed with uterine cervical cancer in the United States between 2010--2015, and included 19,363 women with cervical cancer who had an incidence of bone metastases at diagnosis of 2.42% (N=469).

Patients with cancer of the uterine cervix have been reported to have a relatively lower incidence of bone metastases when compared with cancer of the breast, lung, and prostate \[[@b17-medscimonit-24-6387]--[@b19-medscimonit-24-6387]\]. The present study showed that 2.42% of the study cohort of women with cervical cancer had bone metastases when initially diagnosed, which was a similar finding to that of the study conducted by Thanapprapasr et al. (1.1%) \[[@b6-medscimonit-24-6387]\], but was lower than that found in other studies \[[@b8-medscimonit-24-6387],[@b20-medscimonit-24-6387],[@b21-medscimonit-24-6387]\]. The variety of detection methods used may partly cause the difference in the reported incidence of bone metastases in women with cervical cancer \[[@b6-medscimonit-24-6387],[@b7-medscimonit-24-6387],[@b22-medscimonit-24-6387]\]. However, using the clinical data from the SEER database, it was not possible to determine which imaging or other detection methods were used to identify bone metastases. There have been few previously reported studies on the risk factors for bone metastases in women with cancer of the uterine cervix, but a previous study showed that older age and a higher International Federation of Gynecology and Obstetrics (FIGO) stage was significantly associated with the development of bone metastases \[[@b11-medscimonit-24-6387]\]. Also, in the present study, analysis of the large patient sample size showed that a higher tumor grade and stage, including a higher N-stage, non-squamous and non-adenocarcinoma histological type, and the presence of lung, liver, and brain metastases were also significantly associated with the development of bone metastases. These factors might be of clinical value in identifying patients with cervical cancer who are at high risk for the occurrence of bone metastases. For women who are diagnosed with cervical cancer, skeletal radiographic scanning for high-risk patients with cervical cancer might be used in screening for the presence of bone metastases.

Also, the identification of the prognostic factors associated with the presence of bone metastases in women with cervical cancer might help physicians to provide targeted treatment strategies for patients at different levels of risk and improve patient survival and quality of life. To the best of our knowledge, this study is the first to show that lung, liver, and brain metastases were negatively associated with overall survival in patients with cervical cancer who have bone metastases. The results were similar to the findings from studies conducted in other cancers with bone metastases, such as breast cancer \[[@b23-medscimonit-24-6387],[@b24-medscimonit-24-6387]\].

Previous studies have shown that the number of metastatic sites was an independent prognostic factor and that more sites for tumor metastases resulted in a worse patient prognosis \[[@b24-medscimonit-24-6387],[@b25-medscimonit-24-6387]\]. The present study also showed unmarried status was one of the independent prognosis factors for bone metastases and was negatively associated with overall survival in patients with cancer of the uterine cervix. The following potential explanations are possible. Firstly, married patients may have more opportunity to get prompt diagnosis and treatment due to increased financial support compared with unmarried patients \[[@b26-medscimonit-24-6387],[@b27-medscimonit-24-6387]\]. Married patients may have better support from their family after tumor diagnosis, as is depression and stress have been reported to be significantly associated with tumor metastases \[[@b28-medscimonit-24-6387],[@b29-medscimonit-24-6387]\]. Married patients may have lower opportunity to be infected by human papillomavirus (HPV), which is the main cause of cervical cancer \[[@b16-medscimonit-24-6387],[@b30-medscimonit-24-6387]\].

It has been previously reported that patients with cancer of the uterine cervix who present at under 45 years had shorter overall survival compared with older patients \[[@b16-medscimonit-24-6387]\]. However, contrary to this previous report, we found no significant correlation between age and overall survival when age was stratified into three subgroups. Also, previously published SEER-based analysis has shown that surgery can promote the overall survival of breast \[[@b31-medscimonit-24-6387]\], and colorectal cancer \[[@b25-medscimonit-24-6387]\]. However, no similar association was found in the present study. Further investigations with larger patient population numbers, should be performed to investigate these results further.

This study had several limitations. Firstly, although the presence or absence of bone metastases at the time of the initial diagnosis of cervical cancer was analyzed in the present study, the patients who developed bone metastases later in their disease course could not be analyzed and were not included in the study. Therefore, the real incidence of bone metastases on initial diagnosis of women with cancer of the uterine cervix could have been underestimated. Furthermore, due to the unspecified detection methods used for bone metastases in the cases included in the SEER database, we were not able to compare the different methods. Also, symptoms of bone metastases, including bone pain and pathological fracture have been accepted as the important prognostic factors in other malignancies, but in patients with cervical cancer with bone metastases, these symptoms were not described in detail in the public SEER database and the association between bone symptoms and survival could not be analyzed.

Conclusions
===========

Cancer of the uterine cervix has a relatively lower incidence of metastasis to bone when compared with several other types of cancer. As this study has shown, there are some standard or recognized risk factors associated with bone metastases, and with prognosis, in women with cervical cancer, but a heterogeneous group of risk factors is also present. Risk factors, including an increased stage (T-stage and N-stage), non-squamous and non-adenocarcinoma histological type, poor tumor grade, and the presence of lung, liver and brain metastases, were found to be significantly associated with the finding of bone metastases at the initial diagnosis of cervical cancer. Prognostic factors, including unmarried status, lung metastases, liver metastases and brain metastases, were found to be significantly associated with poor prognosis in cancer of uterine cervix with initial bone metastases. The results of this real-world study may have clinical application in screening for bone metastases when patients present with cervical cancer, with the aim of developing targeted therapy to prevent the development of metastasis to bone in women who present with cancer of the uterine cervix.
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![The homogeneous and heterogeneous risk factors and prognosis factors associated with bone metastases in patients with cancer of the uterine cervix. All the factors included in the left circle represent the risk factors for developing bone metastases. The factors included in the right circle represent the risk factors that were positively associated with overall risk of mortality for patients with uterine cervical cancer with bone metastases.](medscimonit-24-6387-g002){#f2-medscimonit-24-6387}

![Kaplan-Meier analysis of overall survival (OS) among patients with cancer of the uterine cervix who were diagnosed with bone metastases, stratified with other risk factors, and the presence of metastases to other sites. (**A**) Overall survival (OS) for the total population studied. (**B**) Overall survival (OS) stratified by age. (**C**) Overall survival (OS) stratified by marital status. (**D**) Overall survival (OS) stratified by histological grade of the cervical carcinoma. (**E**) Overall survival (OS) stratified by the presence of lung metastases. (**F**) Overall survival (OS) stratified by the presence of liver metastases. (**G**) Overall survival (OS) stratified by the presence of brain metastases. UCC -- uterine cervical cancer; Lung mets -- lung metastases; Livermets -- liver metastases; Brain mets -- brain metastases.](medscimonit-24-6387-g003){#f3-medscimonit-24-6387}

###### 

Baseline demographic and clinical characteristics for patients diagnosed with uterine cervical cancer.

  Subject characteristics                                               No. of cervical cancer patients (2010--2015)   No. of cervical cancer patients (2010--2014)                 
  --------------------------------------------------------------------- ---------------------------------------------- ---------------------------------------------- ------------- ---------------
  Age (years)                                                                                                                                                                       
   ≤40                                                                  57 (1.06)                                      5299 (98.94)                                   49 (1.10)     4398 (98.90)
   41--64                                                               285 (2.76)                                     10058 (97.24)                                  210 (2.46)    8333 (97.54)
   ≥65                                                                  127 (3.47)                                     3537 (96.53)                                   105 (3.46)    2931 (96.54)
  Ethnicity                                                                                                                                                                         
   Caucasian                                                            341 (2.36)                                     14096 (97.64)                                  260 (2.18)    11678 (97.82)
   Black                                                                81 (3.00)                                      2615 (97.00)                                   68 (3.00)     2199 (97.00)
   Others                                                               47 (2.31)                                      1985 (97.69)                                   36 (2.15)     1636 (97.85)
   Unknown                                                              0 (0.00)                                       198 (100.00)                                   0 (0.00)      149 (100.00)
  Marital status                                                                                                                                                                    
   Married                                                              168 (2.13)                                     7719 (97.87)                                   129 (1.97)    6406 (98.03)
   Unmarried                                                            280 (2.73)                                     9985 (97.27)                                   220 (2.59)    8629 (97.41)
   Unknown                                                              21 (1.73)                                      1190 (98.27)                                   15 (1.50)     987 (98.50)
  Insurance status                                                                                                                                                                  
   Insured                                                              420 (2.39)                                     17150 (97.61)                                  325 (2.24)    14153 (97.76)
   Uninsured                                                            38 (3.01)                                      1223 (96.99)                                   30 (2.71)     1076 (97.29)
   Unknown                                                              11 (2.07)                                      521 (97.93)                                    9 (2.04)      433 (97.96)
  T-stage                                                                                                                                                                           
   T1                                                                   62 (0.59)                                      10370 (99.41)                                  46 (0.53)     8621 (99.47)
   T2                                                                   83 (1.96)                                      4156 (98.04)                                   67 (1.92)     3415 (98.08)
   T3                                                                   183 (6.02)                                     2859 (93.98)                                   143 (5.66)    2382 (94.34)
   T4                                                                   59 (8.07)                                      672 (91.93)                                    45 (7.54)     552 (92.46)
   Unknown                                                              82 (8.92)                                      837 (91.08)                                    63 (8.34)     692 (91.66)
  N-stage                                                                                                                                                                           
   N0                                                                   119 (0.87)                                     13523 (99.13)                                  91 (0.80)     11267 (99.20)
   N1                                                                   288 (5.96)                                     4544 (94.04)                                   220 (5.60)    3707 (94.40)
   Unknown                                                              62 (6.97)                                      827 (93.03)                                    53 (7.15)     688 (92.85)
  Histology                                                                                                                                                                         
   Squamous                                                             269 (2.17)                                     12138 (97.83)                                  212 (2.06)    10078 (97.94)
   Adenocarcinoma[\*](#tfn1-medscimonit-24-6387){ref-type="table-fn"}   90 (1.75)                                      5060 (98.25)                                   67 (1.57)     4189 (98.43)
   Others                                                               110 (6.09)                                     1696 (93.91)                                   85 (5.74)     1395 (94.26)
  Grade                                                                                                                                                                             
   I                                                                    9 (0.42)                                       2127 (99.58)                                   6 (0.34)      1751 (99.66)
   II                                                                   78 (1.30)                                      5905 (98.70)                                   63 (1.27)     4895 (98.73)
   III[\#](#tfn2-medscimonit-24-6387){ref-type="table-fn"}              211 (3.54)                                     5744 (96.46)                                   165 (3.35)    4760 (96.65)
   Unknown                                                              171 (3.23)                                     5118 (96.77)                                   130 (2.96)    4256 (97.04)
  Lung mets                                                                                                                                                                         
   None                                                                 265 (1.43)                                     18221 (98.57)                                  208 (1.36)    15112 (98.64)
   Yes                                                                  185 (22.67)                                    631 (77.32)                                    139 (21.38)   511 (78.62)
   Unknown                                                              19 (31.15)                                     42 (68.85)                                     17 (30.36)    39 (69.64)
  Liver mets                                                                                                                                                                        
   None                                                                 328 (1.73)                                     18587 (98.27)                                  258 (1.65)    15400 (98.35)
   Yes                                                                  128 (30.92)                                    286 (69.08)                                    94 (27.98)    242 (72.02)
   Unknown                                                              13 (38.24)                                     21 (61.76)                                     12 (37.50)    20 (62.50)
  Brain mets                                                                                                                                                                        
   None                                                                 423 (2.20)                                     18834 (97.80)                                  329 (2.06)    15609 (97.94)
   Yes                                                                  30 (38.46)                                     48 (61.54)                                     19 (31.15)    42 (68.85)
   Unknown                                                              16 (57.14)                                     12 (42.86)                                     16 (59.26)    11 (40.74)
  Surg (prim)                                                                                                                                                                       
   None                                                                 435 (5.05)                                     8183 (94.95)                                   338 (4.77)    6741 (95.23)
   Yes                                                                  34 (0.32)                                      10677 (99.68)                                  26 (0.29)     8891 (99.71)
   Unknown                                                              0 (0.00)                                       34 (100.00)                                    0 (0.00)      30 (100.00)

Including adenosquamous;

including undifferentiated;

BM -- bone metastases; mets -- metastases; Surg (prim) -- surgical treatment of primary site.

###### 

Univariate and multivariate logistic regression analysis for the associated risk factors for developing bone metastases in patients diagnosed with uterine cervical cancer between 2010--2015.

  Subject characteristics                                               Univariate analysis    Multivariate analysis                        
  --------------------------------------------------------------------- ---------------------- ----------------------- -------------------- ---------
  Age (years)                                                                                                                               
   ≤40                                                                  1 (Reference)          1.00                    1 (Reference)        1.00
   41--64                                                               2.63 (1.98--3.51)      \<0.001                 1.44 (0.95--2.18)    0.08
   ≥65                                                                  3.34 (2.44--4.58)      \<0.001                 1.36 (0.84--2.21)    0.22
  Marital status                                                                                                                            
   Married                                                              1 (Reference)          1.00                    1 (Reference)        1.00
   Unmarried                                                            1.29 (1.06--1.56)      0.01                    0.99 (0.74--1.33)    0.94
   Unknown                                                              NA                     NA                      NA                   NA
  T-stage                                                                                                                                   
   T1                                                                   1 (Reference)          1.00                    1 (Reference)        1.00
   T2                                                                   3.34 (2.40--4.65)      \<0.001                 1.97 (1.25--3.10)    0.003
   T3                                                                   10.71 (8.00--14.32)    \<0.001                 3.86 (2.52--5.91)    \<0.001
   T4                                                                   14.69 (10.20--21.15)   \<0.001                 4.05 (2.36--6.96)    0.001
   Unknown                                                              NA                     NA                      NA                   NA
  N-stage                                                                                                                                   
   N0                                                                   1 (Reference)          1.00                    1 (Reference)        1.00
   N1                                                                   7.20 (5.80--8.94)      \<0.001                 2.89 (2.09--4.00)    \<0.001
   Unknown                                                              NA                     NA                      NA                   NA
  Histology                                                                                                                                 
   Squamous                                                             1 (Reference)          1.00                    1 (Reference)        1.00
   Adenocarcinoma[\*](#tfn4-medscimonit-24-6387){ref-type="table-fn"}   0.80 (0.63--1.02)      0.07                    1.17 (0.81--1.69)    0.40
   Others                                                               2.93 (2.33--3.67)      \<0.001                 1.87 (1.24--2.82)    0.003
  Grade                                                                                                                                     
   I                                                                    1 (Reference)          1.00                    1 (Reference)        1.00
   II                                                                   3.12 (1.56--6.24)      0.001                   1.66 (0.73--3.77)    0.23
   III[\#](#tfn5-medscimonit-24-6387){ref-type="table-fn"}              8.68 (4.45--16.95)     \<0.001                 2.72 (1.23--6.04)    0.01
   Unknown                                                              NA                     NA                      NA                   NA
  Lung metastases                                                                                                                           
   None                                                                 1 (Reference)          1.00                    1 (Reference)        1.00
   Yes                                                                  20.16 (16.44--24.72)   \<0.001                 5.00 (3.54--7.06)    \<0.001
   Unknown                                                              NA                     NA                      NA                   NA
  Liver metastases                                                                                                                          
   None                                                                 1 (Reference)          1.00                    1 (Reference)        1.00
   Yes                                                                  25.36 (20.04--32.09)   \<0.001                 6.25 (4.10--9.54)    \<0.001
   Unknown                                                              NA                     NA                      NA                   NA
  Brain metastases                                                                                                                          
   None                                                                 1 (Reference)          1.00                    1 (Reference)        1.00
   Yes                                                                  27.83 (17.44--44.36)   \<0.001                 7.21 (3.10--16.74)   \<0.001
   Unknown                                                              NA                     NA                      NA                   NA

Including adenosquamous;

including undifferentiated;

NA -- not available. All factors with unknown data were removed from the univariate and multivariate logistic regression model.

###### 

Multivariate Cox regression analysis for the associated risk factors for developing bone metastases in patients diagnosed with uterine cervical cancer between 2010--2014.

  Subject characteristics                                               Survival, Median (IQR), months   HR (95% CI)         P-value
  --------------------------------------------------------------------- -------------------------------- ------------------- ---------
  Age (years)                                                                                                                
   ≤40                                                                  7.00 (4.50--9.50)                1 (Reference)       1.00
   41--64                                                               7.00 (5.84--8.16)                0.87 (0.61--1.24)   0.44
   ≥65                                                                  4.00 (3.16--4.85)                1.18 (0.88--1.58)   0.44
  Marital status                                                                                                             
   Married                                                              10.00 (7.10--12.90)              1 (Reference)       1.00
   Unmarried                                                            5.00 (4.11--5.89)                1.34 (1.04--1.72)   0.02
   Unknown                                                              NA                               NA                  NA
  Histology                                                                                                                  
   Squamous                                                             6.00 (4.83--7.17)                1 (Reference)       1.00
   Adenocarcinoma[\*](#tfn7-medscimonit-24-6387){ref-type="table-fn"}   5.00 (2.33--7.67)                0.90 (0.65--1.24)   0.51
   Others                                                               4.00 (2.90--5.10)                1.18 (0.88--1.58)   0.27
  Lung metastases                                                                                                            
   None                                                                 8.00 (5.87--10.12)               1 (Reference)       1.00
   Yes                                                                  4.00 (3.05--4.95)                1.48 (1.15--1.89)   0.002
   Unknown                                                              NA                               NA                  
  Liver metastases                                                                                                           
   None                                                                 7.00 (5.65--8.34)                1 (Reference)       1.00
   Yes                                                                  4.00 (2.26--5.74)                1.42 (1.07--1.87)   0.02
   Unknown                                                              NA                               NA                  NA
  Brain metastases                                                                                                           
   None                                                                 6.00 (5.05--6.96)                1 (Reference)       1.00
   Yes                                                                  2.00 (0.64--3.37)                2.64 (1.57--4.43)   \<0.001
   Unknown                                                              NA                               NA                  NA

Including adenosquamous.

IQR -- interquartile range; HR -- hazard ratio; CI -- confidence interval; NA -- not available. All factors with unknown data were removed from Cox and Kaplan-Meier model.
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